[Changhe Group] Yangtze Life Technology establishes Shunpu Pharmaceutical Technology, focusing on promoting the development of cancer vaccines, considering expanding R&D facilities in the Northern metropolitan area

2026-03-10 12:20:37

Abstract generation in progress

Yangtze River Life Sciences (00775) announced the establishment of a wholly owned subsidiary, Sequencio Therapeutics, focused on advancing its portfolio of therapeutic cancer vaccines. The group also mentioned that it will assess the situation and actively consider expanding R&D facilities in the Northern Metropolis innovation zone for long-term development.

In recent years, the company has successively reached agreements with two NASDAQ-listed companies

The group stated that this is the third major pillar of the company’s strategic restructuring. Following the company’s deals in 2024 and 2025 with two NASDAQ-listed companies, TransCode Therapeutics (NASDAQ: RNAZ) and Dogwood Therapeutics (NASDAQ: DWTX), this represents another strategic move. Through this series of strategic arrangements, the company aims to accelerate R&D progress, improve operational efficiency, and broaden financing channels for pharmaceutical and diagnostic research, further establishing Yangtze River Life Sciences’ leading position in the field of therapeutic cancer vaccines.

The company mentioned that Sequencio is a platform for developing therapeutic cancer vaccines. By establishing Sequencio, Yangtze River Life Sciences consolidates its therapeutic cancer vaccine R&D projects into a focused platform. The subsidiary specializes in developing therapeutic vaccines that activate the patient’s immune system to fight cancer cells, addressing key limitations of existing standard therapies.

Vice Chairman Yu Yingcai stated that they hope innovative treatments can benefit patients in urgent need as soon as possible. Meanwhile, as R&D projects mature, they will assess the situation and actively consider expanding R&D facilities in the Northern Metropolis innovation zone for long-term planning.

The company added that both NASDAQ-listed companies are led by experienced scientific and commercial teams, which will help more effectively connect with the US capital markets and identify potential strategic partners, accelerating R&D progress. At the same time, Yangtze River Life Sciences’ business revenue can also provide initial and backup funding for internal preclinical research projects integrated into Sequencio.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.